295 related articles for article (PubMed ID: 33979777)
1. Target therapies plus somatostatin analogs in NETs: a network meta-analysis.
Pusceddu S; Facciorusso A; Giacomelli L; Prinzi N; Corti F; Niger M; Milione M; Coppa J; Cascella T; Pulice I; Biamonte L; Papa S; Di Bartolomeo M; Shah A; Sacco R; de Braud F
Endocr Relat Cancer; 2021 Jun; 28(7):467-479. PubMed ID: 33979777
[TBL] [Abstract][Full Text] [Related]
2. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
[TBL] [Abstract][Full Text] [Related]
3. Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study.
Capdevila J; Teulé A; Barriuso J; Castellano D; Lopez C; Manzano JL; Alonso V; García-Carbonero R; Dotor E; Matos I; Custodio A; Casanovas O; Salazar R;
Oncologist; 2019 Jan; 24(1):38-46. PubMed ID: 29794066
[TBL] [Abstract][Full Text] [Related]
4. Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis.
Walter MA; Nesti C; Spanjol M; Kollár A; Bütikofer L; Gloy VL; Dumont RA; Seiler CA; Christ ER; Radojewski P; Briel M; Kaderli RM
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013700. PubMed ID: 34822169
[TBL] [Abstract][Full Text] [Related]
5. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Options for Neuroendocrine Tumors: A Systematic Review and Network Meta-analysis.
Kaderli RM; Spanjol M; Kollár A; Bütikofer L; Gloy V; Dumont RA; Seiler CA; Christ ER; Radojewski P; Briel M; Walter MA
JAMA Oncol; 2019 Apr; 5(4):480-489. PubMed ID: 30763436
[TBL] [Abstract][Full Text] [Related]
7. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.
Kulke MH; Ruszniewski P; Van Cutsem E; Lombard-Bohas C; Valle JW; De Herder WW; Pavel M; Degtyarev E; Brase JC; Bubuteishvili-Pacaud L; Voi M; Salazar R; Borbath I; Fazio N; Smith D; Capdevila J; Riechelmann RP; Yao JC
Ann Oncol; 2017 Jun; 28(6):1309-1315. PubMed ID: 28327907
[TBL] [Abstract][Full Text] [Related]
8. [
Spada F; Campana D; Lamberti G; Laudicella R; Dellamano R; Dellamano L; Leeuwenkamp O; Baldari S
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2037-2048. PubMed ID: 34950969
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
10. Resistance of neuroendocrine tumours to somatostatin analogs.
Angelousi A; Koumarianou A; Chatzellis E; Kaltsas G
Expert Rev Endocrinol Metab; 2023 Jan; 18(1):33-52. PubMed ID: 36651768
[TBL] [Abstract][Full Text] [Related]
11. Everolimus plus octreotide long-acting repeatable in advanced neuroendocrine tumors in the routine tertiary cancer care setting: An Indian experience.
Tippeswamy R; Patil S; Sateesh CT; Shashidhara HP; Prabhudesai S; Prashanth P; Haridas KM
Indian J Cancer; 2015; 52(3):359-62. PubMed ID: 26905137
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.
Oberg K
Expert Rev Anticancer Ther; 2009 May; 9(5):557-66. PubMed ID: 19445573
[TBL] [Abstract][Full Text] [Related]
13. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
Cives M; Strosberg J
Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.
Capdevila J; Sevilla I; Alonso V; Antón Aparicio L; Jiménez Fonseca P; Grande E; Reina JJ; Manzano JL; Alonso Lájara JD; Barriuso J; Castellano D; Medina J; López C; Segura Á; Carrera S; Crespo G; Fuster J; Munarriz J; García Alfonso P
BMC Cancer; 2015 Jul; 15():495. PubMed ID: 26138480
[TBL] [Abstract][Full Text] [Related]
15. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
Del Rivero J; Perez K; Kennedy EB; Mittra ES; Vijayvergia N; Arshad J; Basu S; Chauhan A; Dasari AN; Bellizzi AM; Gangi A; Grady E; Howe JR; Ivanidze J; Lewis M; Mailman J; Raj N; Soares HP; Soulen MC; White SB; Chan JA; Kunz PL; Singh S; Halfdanarson TR; Strosberg JR; Bergsland EK
J Clin Oncol; 2023 Nov; 41(32):5049-5067. PubMed ID: 37774329
[TBL] [Abstract][Full Text] [Related]
16. Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial.
Anthony LB; Pavel ME; Hainsworth JD; Kvols LK; Segal S; Hörsch D; Van Cutsem E; Öberg K; Yao JC
Neuroendocrinology; 2015; 102(1-2):18-25. PubMed ID: 25824001
[TBL] [Abstract][Full Text] [Related]
17. Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors.
Diamantopoulos LN; Laskaratos FM; Kalligeros M; Shah R; Navalkissoor S; Gnanasegaran G; Banks J; Smith J; Jacobs B; Galanopoulos M; Mandair D; Caplin M; Toumpanakis C
Neuroendocrinology; 2021; 111(7):650-659. PubMed ID: 32541155
[TBL] [Abstract][Full Text] [Related]
18. Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story.
Faggiano A
J Endocrinol Invest; 2024 Jan; 47(1):35-46. PubMed ID: 37581846
[TBL] [Abstract][Full Text] [Related]
19. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
[TBL] [Abstract][Full Text] [Related]
20. Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis.
Merola E; Panzuto F; Delle Fave G
Oncotarget; 2017 Jul; 8(28):46624-46634. PubMed ID: 28402955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]